Huashi Baidu Granule in the Treatment of Pediatric Patients With Mild Coronavirus Disease 2019
Status:
Completed
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
The investigators conducted a single-center, open-label, parallel-group randomized controlled
trial to assess the efficacy and safety of a Chinese herb compound granule Huashi Baidu
granule (HSBDG) in pediatric patients with laboratory-confirmed mild COVID-19. 108 recruited
children (aged 3 to 18 years) with laboratory-confirmed mild COVID-19 were randomly allocated
2:1 to receive oral HSBDG for 5 consecutive days (intervention group) and to receive compound
pholcodine oral solution for 5 consecutive days (control group). The negative conversion time
of SARS-CoV-2 nucleic acid and symptom scores were recorded.